logo
GM slow-rolls its all-EV aspirations

GM slow-rolls its all-EV aspirations

Politico12-06-2025
General Motors quietly closed the door this week on a goal to make only electric vehicles by 2035.
The automaker announced Tuesday that it would spend $4 billion on mostly gasoline-powered vehicles. While GM is not retreating from EVs, the investment means the company is 'giving up any hope of achieving that [2035] goal,' said Sam Abuelsamid, an auto analyst at Telemetry, a Detroit-area research firm.
Asked Wednesday whether the goal still exists, GM said in a statement, 'We still believe in an all-EV future.'
GM's move away from the 2035 goal is less a singular failure and more a symptom of flagging support among many actors, including government, other automakers, charging companies and car buyers, analysts said.
Much has changed since GM set the EV target, just after President Joe Biden took office and amid a surge of confidence in the auto industry about widespread EV adoption. Four years later, the Trump administration is dismantling Biden-era federal support for EVs and implementing high tariffs, upsetting automakers' production plans.
Those federal moves, combined with a cooling desire for EVs among car buyers, has moved the sunset date for the internal combustion engine to a vague someday.
GM is still ramping up EV production. Earlier this week, it trumpeted the fact that it sold 37,000 EVs in the first quarter of the year, making it the number two EV maker in the U.S. behind Tesla.
The company's 2035 goal 'was aspirational. It was more an idea than a strategy,' said Alan Baum, an independent Detroit auto analyst. 'GM's doing a better job than many of their competitors, but there's obviously a relatively low ceiling because of the lack of supportive policy.'
GM's all-EV goal back in 2021 was one of the earliest and most prominent of a wave of automaker commitments to electric vehicles. At the time, GM CEO Mary Barra encouraged others to 'follow suit and make a significant impact on our industry and on the economy as a whole.'
Others did follow — and all of those promises have been tempered by new realities.
Last year, European automakers Volvo, Porsche, Volkswagen and Mercedes all dropped earlier goals that would have seen them producing all or mostly EVs by the early 2030s.
Back in 2021, GM also put an asterisk on its 2035 target.
'We say it as an aspirational goal, because to actually make that timing, we need some external things to come together also,' spokesperson Jessica James said at the time.
Barra reiterated last month that the company still wants an 'all-EV future.'
'EVs are fundamentally better,' she said at a Wall Street Journal event late last month. 'We have work to do to continue to get battery technology to give us greater density, so we have farther range. We need to have a robust charging infrastructure.'
Automakers, including GM, have been mostly mum in public as the Trump administration and Republicans in Congress seek to kill tax incentives that make it cheaper for manufacturers to produce batteries and consumers to buy EVs.
But through the main U.S. automotive lobby, the Alliance for Automotive Innovation, automakers have vociferously opposed California's plans to require all-electric auto sales by 2035.
The Republican-controlled Congress voted to kill that California 2035 all-EV sales goal — the same one that GM first set for itself — through the Congressional Review Act. The move came after the Senate parliamentarian told lawmakers they couldn't repeal the goal through the CRA.
The bill awaits a signature by Trump, after which the California attorney general has pledged to sue.
GM's announcement that it would invest $4 billion in domestic manufacturing essentially shuffles production among factories in ways that will help the company dodge Trump's tariffs.
It is moving production of about a half-million gasoline-powered vehicles from Mexico to factories in the U.S., according to an analysis by Abuelsamid of Telemetry. Doing so will enable GM to avoid 25 percent tariffs that the Trump administration has placed on vehicles imported from Mexico.
For example, the production of several full-size SUVs and pickup trucks will transfer to GM's Orion plant, north of Detroit. The gas-powered Equinox, a strong U.S. seller, will move to the Fairfax plant in Kansas City. The gas-running Blazer will go to the company's Spring Hill plant in Tennessee.
Meanwhile, more EV production will move to GM's Factory Zero, a dedicated EV plant in metro Detroit that is running far below capacity. Electric versions of the Chevrolet Silverado and GMC Sierra pickup trucks will now get made in the plant, alongside other large EVs made in low volumes, including the Cadillac Escalade IQ and the Hummer.
Other EVs will be made elsewhere. Other electric Cadillacs, for example, will be made at the Spring Hill plant, while a rebooted version of the Chevy Bolt will be produced at the Fairfax plant, which the company described as the site for the 'next generation of affordable EVs.'
Those changes, combined with other recent moves, make it clear that GM is laying the groundwork to produce gas-powered vehicles well into the 2030s.
In May, the Detroit automaker said it would ditch plans to make electric motors at its Towanda Production plant in Buffalo, New York, and instead spend $888 million to make V-8 engines.
In 2023, GM put $579 million toward refurbishing an engine plant in Flint, Michigan. Electric vehicles don't have engines — they rely instead on batteries for propulsion.
Engine factories are large, fixed investments that are meant to operate for 15 years or more, according to Neal Ganguli, a managing director and auto-manufacturing expert at the business advisory firm AlixPartners.
Meanwhile, the manufacturing lines that make finished cars — like the ones GM unveiled this week — have shorter but still lengthy lives.
'When you put these [manufacturing lines] in, you are planning on a five- to seven-year time horizon,' Ganguli said. 'Maybe 10 years.'
Analysts said General Motors' swerve back into the gasoline lane — and away from the path to all EVs by 2035 — is not a surprise, given the market and policy realities.
'It was always a long shot at best,' said Abuelsamid.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why Investors Were So Fired Up About First Solar Stock on Friday
Why Investors Were So Fired Up About First Solar Stock on Friday

Yahoo

time17 minutes ago

  • Yahoo

Why Investors Were So Fired Up About First Solar Stock on Friday

Key Points Data center operators are unhappy with potential changes to federal incentives for green energy solutions. A group of them are lobbying the Trump administration to leave these incentives alone for now. 10 stocks we like better than First Solar › The solar industry has struggled mightily for years to achieve meaningful growth and post net profits. During the Biden administration, the green energy sector as a whole received something of a break in the 2022 Inflation Reduction Act, with a slew of tax incentives for building out alternative-energy solutions. In its attempt to reverse this, President Donald Trump has tasked his administration to make the current subsidies harder to obtain. Thankfully for green energy companies, a theoretically influential lobbying group stepped in on Friday to push back against this effort. Numerous solar stocks popped on the news, including First Solar (NASDAQ: FSLR), which rose a sturdy 11% by market close. A mighty lob by a lobbying group The business grouping behind Friday's pushback is the Data Center Coalition. News broke that the coalition sent a formal request to Treasury Secretary Scott Bessent to maintain the subsidy policy as it is, rather than changing it. The organization -- which lists as members Amazon, Oracle, and CoreWeave, among other prominent tech companies -- told Bessent that any regulatory roadblock limiting green energy solutions will hamper the development of artificial intelligence (AI). Many data center operators are currently building out their facilities to handle the vastly increased resource demands of AI. To do so, they require more energy, hence their support of renewable sources like solar. Does the silence speak volumes? Bessent hasn't yet publicly responded to the coalition's lobbying effort, nor has anyone else in the Trump administration. But investors seem convinced that they've not only digested the letter, they're taking it seriously, since the organization behind it has many prominent members who drive the U.S. economy. Should you invest $1,000 in First Solar right now? Before you buy stock in First Solar, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and First Solar wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $663,630!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,695!* Now, it's worth noting Stock Advisor's total average return is 1,071% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, First Solar, and Oracle. The Motley Fool has a disclosure policy. Why Investors Were So Fired Up About First Solar Stock on Friday was originally published by The Motley Fool

China's Biotech Is Cheaper and Faster
China's Biotech Is Cheaper and Faster

New York Times

time35 minutes ago

  • New York Times

China's Biotech Is Cheaper and Faster

Just outside of Shanghai, in the city of Wuxi, China is building its future of medicine — a booming biotechnology hub of factories and laboratories where global pharmaceutical companies can develop and manufacture drugs faster and cheaper than anywhere else. Amid the Trump administration's tariffs on China, I figured manufacturing hubs like this one would be wracked with anxiety. But when I visited Wuxi in April, government officials insisted that its research hub was flourishing. They were proud to tell me about their superstar labs and companies that are continuing to thrive. The fact that Chinese biotechnology stocks have surged over 60 percent since January seems to bolster this claim. The city's researchers certainly seemed positioned to be busy for decades. In its quest to dethrone American dominance in biotech, China isn't necessarily trying to beat America at its own game. While the U.S. biotech industry is known for incubating cutting-edge treatments and cures, China's approach to innovation is mostly focused on speeding up manufacturing and slashing costs. The idea isn't to advance, say, breakthroughs in the gene-editing technology CRISPR; it's to make the country's research, development, testing and production of drugs and medical products hyperefficient and cheaper. As a result, China's biotech sector can deliver drugs and other medical products to customers at much cheaper prices, including inexpensive generics. These may not be world-changing cures, but they are treatments that millions of people around the world rely on every day. And as China's reach expands, the world will soon have to reckon with a new leader in biotech and decide how it wants to respond. One such company that embodies the Chinese approach to biotech is Wuxi AppTec. It's a one-stop shop for pharmaceutical research and development, streamlining everything from early-stage drug discovery to young scientist recruitment and medication production. The company, whose clients have included Chinese firms like Innovent and Jiangsu Hengrui, as well as American and European drugmakers like Pfizer, GlaxoSmithKline and AstraZeneca, was involved in, by one estimate, a quarter of the drugs used in the United States, including blockbuster cancer drugs. Though the Chinese government bargains hard with both foreign and domestic pharmaceutical companies to provide products at the right price in exchange for market access, the low prices that Chinese consumers pay are ultimately the result of Chinese biotech companies' ability to test and manufacture drugs at a pace far faster than their American counterparts. So far, American biotech giants don't seem to mind the competition, since their own use of companies like Wuxi AppTec allows them to dedicate more of their money to breakthrough research. Want all of The Times? Subscribe.

What's Driving the Wild Swings in Tilray Stock (TLRY)?
What's Driving the Wild Swings in Tilray Stock (TLRY)?

Business Insider

timean hour ago

  • Business Insider

What's Driving the Wild Swings in Tilray Stock (TLRY)?

Shares of Tilray Brands (TLRY) kicked off last week on a positive note after President Donald Trump said he is considering a proposal to reclassify marijuana as a less dangerous drug. Nonetheless, the stock ended the week with a 10.5% drop on Friday. Overall, TLRY stock has gained nearly 35% over the past five trading days, though it remains down more than 30% year-to-date. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. For context, Tilray Brands produces and distributes cannabis, hemp-based foods, and alcoholic beverages across multiple markets. What's Behind TLRY's Moves? Speaking to reporters in the White House briefing room, Trump said the review of marijuana's classification is in progress, and a decision could come within the next few weeks. He added that he hopes the decision 'will be the right one.' The proposed change would move marijuana to Schedule III, which is a category for drugs with accepted medical uses and lower abuse potential. Right now, U.S. law classifies cannabis as a Schedule I drug under the Controlled Substances Act, putting it in the same category as highly dangerous drugs like heroin. Nonetheless, the proposal is currently under review by the U.S. Drug Enforcement Administration (DEA). Separately, Tilray confirmed it is seeking an extension from Nasdaq to regain listing compliance. This disclosure has likely fueled volatility and contributed to the price reversal on Friday. What Does It Mean for TLRY? If marijuana is reclassified as less dangerous, it could lift TLRY stock by easing rules for cannabis companies in the U.S. Such a change would ease restrictions, expand medical and commercial opportunities, and attract more investors. Overall, TLRY stock has remained volatile in the past year. However, a move of this size is rare even for Tilray, suggesting the news had a major impact on how the market views the company. Is TLRY a Good Buy? TLRY stock based on two Buys and four Holds assigned in the past three months. Furthermore, the average Tilray stock price target of $0.94 per share implies a downside of over 10% from the current level.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store